Regen BioPharma expands Its differentiation therapy of cancer stem cells platform

(MENAFN- ProactiveInvestors) Regen BioPharma (OTCBB:RGBP) a biotechnology company announced the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII) a closely related family member to the cancer stem cell gene NR2F6 with the filing of two patent applications. 

Patent application #14588374 is for treatment of myelodysplastic syndrome (MDS) by inhibition of NR2F2 and patent application # 14588373 is for methods and compositions for treatment of cancer by inhibition of NR2F2 the San Diego California-based company said in a statement today.

Patent application #14588374 covers methods compositions and treatment protocols for the treatment of MDS. This patent application also covers induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition to reduce the state of MDS and/or in other embodiments to inhibit or revert progression to leukemic states Regen said. 

Patent application #14588373 covers utilizing of gene silencing technologies pertaining to suppression of the nuclear receptor NR2F2 for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors and methods of using such compounds to treat cancer.

These new patent applications add to the company's existing portfolio of intellectual property covering therapeutics that can be used as differentiation therapy a new form of cancer treatment that works by instructing cancer stem cells to mature in to normal cells that have a limited lifespan. 

This intellectual property will compliment other intellectual property in the gene silencing of cancer stem cells therapeutics platform including in-house and acquired IP from the University of Toronto for the cancer stem cell gene NR2F6 (also known as EAR-2) and the company's CTCFL technology also known as BORIS).

“We are working on establishing an area of expertise in gene silencing of cancer stem cell target genes that builds upon a licensing agreement with Benitec Biopharma for use in conjunction with their shRNA gene silencing platform” chief executive officer David Koos said in the statement. 

“This allows us to take advantage of synergisms by establishing strengths and programs that we can use to comprehensively target the important genes in the cancer stem cell space. This will lead to economies of scale in therapy development.”

The cancer stem cell is the most important and sought after cellular target of cancer therapy. Not every cancer cell within a tumour is able to divide. Cancer stem cells are the cells within the tumour that can divide an infinite number of times and are the cells within the tumour that allow a tumour to maintain its cancerous ability therefore it is important to target those cells specifically.

"Patent protection is also essential for thoroughly protecting the Company's space in this field” chief scientific officer Thomas Ichim said in the statement. 

“While existing patents cover NR2F6 a closely related member of that protein family NR2F2 has some redundant and overlapping functions. Protecting this space is important not only to cover our target but because resistance of the cancer to therapy is one the biggest causes of cancer therapy failure.”

Shares rose 5.8 percent to $0.230 at 1:42 p.m. in Toronto expanding this year’s rally to 57 percent.

NR2F2 (COUP-TFII) is well known for its role in cancer by the mechanism of controlling key pathways in embryogenesis and tumour formation including the Notch signalling pathway TGF-beta and retinoic acid signalling.

Regen BioPharma seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.